论文部分内容阅读
慢性肝炎患者有肝炎病毒持续性感染及体内病毒难于排除空体外的免疫异常,其治疗的根本目的是排除体内的病毒。以往对慢性肝炎的治疗只采取保肝疗法,主要是调理饮食加静养为主。近年已开始应用于扰素(IFN)、Ara-A等抗病毒药物及OK-432、Cian-~idanol等免疫增强剂进行病因治疗,并积累了相当的经验。1986年起人们发现干扰素-β对乙型肝炎有治疗作用,并且有推广普及的可能,本文主要对千扰素的治疗现状、存在的问题及今后的展望做一介绍。
Chronic hepatitis patients with persistent hepatitis virus infection and in vivo virus is difficult to rule out the empty body of immune disorders, the treatment of its fundamental purpose is to rule out the body of the virus. In the past, the treatment of chronic hepatitis only taken hepatoprotective therapy, mainly diet and rest mainly. In recent years, it has been used in the treatment of etiology of antiviral drugs such as interferon (IFN) and Ara-A, and immune enhancers such as OK-432 and Cianad idanol, and has gained considerable experience. Since 1986, people have found that interferon-β has a therapeutic effect on hepatitis B, and it is possible to popularize it. This article mainly introduces the treatment status of interferon, existing problems and future prospects.